FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Diabetic Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

SUPPL AP for EYLEA (AFLIBERCEPT)